Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell Therapy for the Treatment of Malignant Solid Brain Tumors
NCT07552233Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2030
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Open-label trial of autologous natural killer cells in Malignant Neoplasm Of Brain, glioblastoma (GBM), brain metastasis (BM) and 1 more (3 arms), sponsored by Peking University Third Hospital. Primary endpoints: Incidence of Adverse Events at 3 months and Incidence of Dose-Limiting Toxicities at 28 days. Started Apr 2026; status: recruiting.
02
Drugs
autologous natural killer cells
03
Conditions
Malignant Neoplasm Of Brainglioblastoma (GBM)brain metastasis (BM)meningioma
Beyond the preview
Go deeper on NCT07552233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552233.